SIGA Technologies

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SIGA Technologies reports strong revenue diversification and growth opportunities

SIGA Technologies delivered robust financial results in 2022, showcasing revenue diversification and positive cash flows. With a focus on TPOXX and upcoming FDA submissions, the company is poised for growth. Challenges lie in regulatory hurdles and operational complexities, but opportunities abound in US Government procurement and international sales expansion.

SIGA Technologies projects robust 2023 performance with strategic growth initiatives

SIGA Technologies is poised for a successful 2023, driven by strong financial expectations and product delivery targets. The company's focus on innovation, strategic partnerships, and market expansion positions it well for future growth. Challenges in negotiations, clinical trials, and program scalability require careful management to capitalize on emerging opportunities.

SIGA Technologies projects robust growth in 2023 amidst operational challenges

SIGA Technologies is poised for strong financial performance in the second half of 2023, with revenue expectations and operating income growth.
The company's focus on TPOXX as a key treatment for orthopoxviruses and international sales growth positions it well for future success.
While facing challenges in trial data analysis and CEO transition, SIGA has opportunities for market expansion and revenue diversification.

SIGA Technologies reports solid Q3 earnings amidst packaging challenges

SIGA Technologies is navigating packaging delays and inventory build-up while maintaining a strong financial position. Promising programs and trials indicate growth potential, with opportunities for additional orders and upsells in the EU market.

SIGA Technologies excels in Q4 2023 earnings, eyes innovation and growth

SIGA Technologies delivered impressive financial results in Q4 2023, with strong revenue growth and profitability. Despite facing challenges in contract extensions and manufacturing capacity, the company remains focused on innovation and expansion to drive future growth and value creation.

SIGA Technologies excels in Q1 2024, navigates health challenges

SIGA Technologies delivered a strong performance in Q1 2024, marked by revenue growth, operational efficiency, and strategic advancements. While maintaining a solid financial position, the company faces challenges related to public health concerns and regulatory complexities. Leveraging opportunities in product expansion and global partnerships will be key to sustaining growth and market leadership.

SIGA Technologies reports robust Q2 earnings and global expansion plans

SIGA Technologies' Q2 2024 performance reflects strong revenue growth and financial stability.
The company's focus on diversification, international expansion, and innovation positions it for future success.
Challenges in government contract negotiations and regulatory approvals are balanced by growth opportunities and positive outlook.

SIGA Technologies reports robust Q3 earnings and eyes global expansion

SIGA Technologies' Q3 2024 earnings call reflects strong financial performance, strategic partnerships, and a focus on innovation and market expansion.
The company's commitment to product safety, efficacy, and diverse revenue sources positions it well for future growth and sustained profitability.
While facing challenges in regulatory approvals and market competition, SIGA's financial stability, product credibility, and growth opportunities present a positive outlook.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

- Approximately $26 Million of Orders Received from Canada underExisting Procurement Contracts – - Approximately $2 Million of Orders Received from Two New Jurisdictions -

SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

Investors may have assumed SIGA stock would rally on a regulatory green light for SIGA Technologies, but the response has been lackluster. The post SIGA Stock Is in Focus Following U.K. Approval of Monkeypox Treatment appeared first on InvestorPlace.

SIGA Stock Is in Focus Following U.K. Approval of Monkeypox Treatment

Treatment Approved for Smallpox, Monkeypox, Cowpox, and Vaccinia Complications Treatment Approved for Smallpox, Monkeypox, Cowpox, and Vaccinia Complications

SIGA Technologies Receives Approval from UK for Tecovirimat

Chimerix

Emergent BioSolutions

Stocks related to the treatment of monkeypox are heating up today on news that the U.S. is building a vaccine stockpile and will offer vaccine appointments to individuals who are at risk of contracting the virus. The post Monkeypox Stocks BVNRY, EBS, CMRX, SIGA Heat Up on U.S. Vaccine Stockpile appeared first on InvestorPlace.

Monkeypox Stocks BVNRY, EBS, CMRX, SIGA Heat Up on U.S. Vaccine Stockpile

SIGA Technologies Inc (NASDAQ: SIGA) has announced approximately $13 million in procurement orders for oral TPOXX (tecovirimat) The order includes $11 million for initial procaurement from two new international jurisdictions and an approximate $2 million order from a country in the.

SIGA Technologies Announces $13M Worth Order For Its Monkeypox Treatment

SIGA Technologies (SIGA) stock is heading higher on Thursday after the company announced $13 million worth of TPOXX orders. The post SIGA Stock Rises After Announcing $13 Million Worth of Orders for Smallpox Drug appeared first on InvestorPlace.

SIGA Stock Rises After Announcing $13 Million Worth of Orders for Smallpox Drug

Orders Received from Two New Jurisdictions, and a Country in the Asia Pacific Region under an Existing Contract Orders Received from Two New Jurisdictions, and a Country in the Asia Pacific Region under an Existing Contract

SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

SIGA to Appear alongside Emergent Biosolutions and Tonix Pharmaceuticals SIGA to Appear alongside Emergent Biosolutions and Tonix Pharmaceuticals

SIGA to Participate in Alliance Global Partners' Monkeypox Panel on Thursday, June 23rd 2022

Abbott Labs

Inovio Pharmaceuticals

Tonix Pharmaceuticals Hld

SIGA Technologies (SIGA) may lead on the list of monkeypox stocks that could soar, but Bavarian Nordic seems to be leading the sales race. The post 7 Monkeypox Stocks That May Take Off in Q2 appeared first on InvestorPlace.

7 Monkeypox Stocks That May Take Off in Q2

Here's why investors in SIGA Technology are cheering as SIGA stock rises more than 40% on today's risk-on price action. The post Why Is SIGA Technologies (SIGA) Stock Up 45% Today?

Why Is SIGA Technologies (SIGA) Stock Up 45% Today?

SIGA Technologies' share price has been soaring as a result of approval for its IV smallpox therapy. The company's TPOXX formulation was also recently approved in Europe for indications including smallpox and monkeypox.

SIGA Technologies: Solid Business With Means To Address Monkeypox Outbreak

Geovax Labs

Wondering what are the best monkeypox stocks to watch? Here are the companies producing vaccines to help fight the spread of the virus.

7 Monkeypox Stocks to Watch Right Now

The monkeypox opportunity could already be baked into the prices of these stocks.

Are These 4 Stocks Smart Buys With the Monkeypox Outbreak?

SIGA stock is sparking investors' interest because SIGA has developed a smallpox treatment, and smallpox is closely related to monkeypox. The post SIGA Stock Is in Focus as Investor Interest in Monkeypox Stocks Grows appeared first on InvestorPlace.

SIGA Stock Is in Focus as Investor Interest in Monkeypox Stocks Grows

SIGA Technologies Inc (NASDAQ: SIGA) shares are trading higher Monday morning following increased social media interest amid elevated concerns surrounding a monkeypox outbreak.  Monkeypox cases have continued to pop up in recent days.

Why SIGA Technologies Stock Is Surging

Fear of another viral outbreak is generating a lot of buzz around these three biotech stocks.

3 Monkeypox Stocks That Soared Last Week

On Friday, May 20, the World Health Organization (WHO) stated that over 80 cases of monkeypox have been confirmed in.

Two US-listed companies that could stop the Monkeypox virus spread

A Monkeypox outbreak has been reported in several European countries, two cases in Canada and one confirmed case in a man from Massachusetts. What's going on?

6 Stocks To Watch Amid Monkeypox Outbreak

Monkeypox stocks SIGA, EBS and TNXP are all advancing as fears mount over monkeypox. The disease is related to smallpox.

Monkeypox Stocks: SIGA, EBS and TNXP Move Higher on Smallpox Vaccines, Treatments

Emergent BioSolutions (EBS) stock was up almost 12% while SIGA Technologies (SIGA) rose 17.1% on Thursday.

Monkeypox Fears Drive Smallpox Antiviral Makers Higher

The FDA approved the intravenous (IV) formulation of SIGA Technologies Inc's (NASDAQ: SIGA) TPOXX for smallpox. The oral formulation of TPOXX (tecovirimat) is approved in the US, Canada, and Europe to treat smallpox.

Why SIGA Technologies Shares Are Trading Higher Today?

Grab Holdings Ltd

The tech-heavy index held up better than the rest of the market.

Why These 2 Nasdaq Stocks Soared Thursday

- FDA approval provides an important option for those unable to take oral formulation of TPOXX - - FDA approval provides an important option for those unable to take oral formulation of TPOXX -

SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)

NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Department of Defense (DoD) awarded a contract to SIGA for the procurement of up to approximately $7.5 million of oral TPOXX, of which approximately $3.6 million of oral TPOXX is targeted for delivery in 2022 and the remainder is subject to an option at the sole discretion of the DoD.

New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX®

SIGA Technologies, Inc. (NASDAQ:SIGA ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Phillip Gomez - Chief Executive Officer Dan Luckshire - Chief Financial Officer Dennis Hruby - Executive Vice President & Chief Scientific Officer Conference Call Participants Ken Mestemacher - Edison Group Operator Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.

News for SIGA Technologies Stock (SIGA)